Form 4: Corcept Therapeutics Officer Lyon Reports Share Transactions

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, reported the acquisition and disposal of company shares on December 2, 2024.

Summary

• Joseph Douglas Lyon, Chief Accounting & Technology Officer at Corcept Therapeutics, engaged in several transactions involving the company's common stock on December 2, 2024.
• 165 shares were disposed of at $57.68 per share to cover withholding obligations related to vesting restricted stock units.
• 215 shares were purchased at $59.21 per share under a company purchase plan.
• An additional 215 shares were granted as restricted stock awards under the same purchase plan.
• Following these transactions, Lyon's total direct holdings increased to 8,759 shares, including unvested restricted stock awards.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The officer's purchase of shares indicates confidence, while the disposal for tax obligations is a routine event.

Positives

• The purchase of 215 shares by the officer demonstrates confidence in the company's future.
• The purchase plan allows employees to acquire shares at a set price, aligning their interests with shareholders.

Risks

• The disposal of shares to cover tax obligations could be seen as a minor negative signal, although it is a common practice.
• The vesting of restricted stock awards is contingent on the officer remaining with the company for one year.

Future Outlook

The restricted stock awards will vest on the one-year anniversary of the grant date, provided the officer remains with the company.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company officers.

Comparison to Industry Standards

• The share transactions are typical for executives at publicly traded companies, often involving stock options, restricted stock units, and share purchase plans.
• Similar filings are regularly made by officers at comparable companies such as Exelixis, Inc. and Incyte Corporation, reflecting standard practices for executive compensation and share ownership.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the trading activities of company officers.
• The purchase plan aligns the interests of employees with those of shareholders.

Key Dates

Keywords

Corcept Therapeutics, CORT, insider trading, share transactions, restricted stock, officer, Joseph Douglas Lyon, stock purchase plan